ASX Announcements
Market Sensitive
FY25 Half Year Report (including Appendix 4D)
Half Yearly Report, Half Year Audit Review, Half Year Directors' Statement, Half Year Accounts, Half Year Directors' Report
FY25 Half Year Results Announcement Details
Notification of Results/Reporting Date, Web Casts
Market Sensitive
Appendix 4C and Quarterly Activity Report -31 December 2024
CTE – Second Quarter Cashflow Report, CTE - Second Quarter Activity Report
December 2020
The green whistle blows for Gordon Naylor’s next move
Former CSL CFO and Seqirus boss Gordon Naylor says all employees need to understand the financial state of a business.
Medical Developments seeks $30m in fresh capital
Gordon Naylor, the incoming chairman of the biotech, says there are parallels with ASX giant CSL, where he worked for three decades.
Bell Potter lines up investors for Medical Developments
Emergency pain relief products maker Medical Developments is after $30 million fresh capital via Bell Potter.
August 2020
Medical Developments buys back European 'green whistle' rights
The ASX minnow's current distribution partner's parent, Purdue Group, is dealing with numerous legal cases relating to the opioid epidemic in the United States.
November 2019
Medical Developments surges on China approval
The company's submission in China is to have Penthrox approved for two separate indications: trauma pain and procedural pain.
August 2018
Bell Potter launches Medical Developments placement at skinny discount
Emergency pain relief and respiratory products company Medical Developments International is in front of fund managers seeking an equity injection to fund growth.
April 2017
Medical Developments pens deals with Walmart and Kmart
Medical Developments has penned deals with US giants Walmart and Kmart to sell several of its respiratory device products.
June 2016
Election 2016: CSIRO Manufacturing wrote Turnbull's script
CSIRO Manufacturing's partnership with Boron Molecular is the kind of industry-research collaboration the PM wants to nurture.
August 2014
What microcap fund managers like
Despite microcap managers being wary of disclosing their key investments, we highlight the stocks liked by five specialist funds.
January 2013
Westpac, NAB hybrid issues next off the rank
Bankers are bracing for another frantic February in the hybrid market as the big banks eye retail targeted capital tier one raisings.
Pharmas in favour: Medical Developments eyed
With resources on the nose, investor attention turns to pharmaceutical companies that earn foreign currency and are less affected by the Australian dollar.